JOHNSON & JOHNSON $85.63

up +0.72


17/6/2013 04:17 PM  |  NYSE : JNJ  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
Get Trend Analysis Icon Get JNJ Trend Analysis - it has outperformed the S&P 500 by 7%

Partner Headlines

  1. Berkshire Adds Archer-Daniels, Verisign; Boosts GM Stake

    Benzinga

  2. 15 Dividend Kings - Stocks with the Longest Dividend Growth History

    GuruFocus

  3. The World's Best Dividend Portfolio

    GuruFocus

  4. Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

    Benzinga

  5. To All You Cash-Laden Companies: Where are the Stock Buybacks?

    YCharts

  6. UPDATE: Credit Suisse Downgrades Johnson & Johnson to Underperform ...

    Benzinga

  7. Johnson & Johnson Breaks Out Over $75 Resistance

    Benzinga

  8. Is My Doctor On the Payroll of Some Drug Maker? Now Easier to Find Out

    YCharts

  9. Buying What Buffett Sells? Sometimes it Works

    Benzinga

  10. Pay-to-Delay Charges Against J&J and Novartis in Europe: U.S. ...

    YCharts

  11. Why I Bought Johnson & Johnson (JNJ)

    GuruFocus

  12. Look Beyond P/E Ratios, Dividend Investors

    GuruFocus

  13. J&J CEO Gorsky and Scandals: An Assessment

    YCharts

  14. 2 Attractively Valued Blue Chips

    Benzinga

  15. Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

    Benzinga

  16. Bright Horizons Soars In IPO, Priced Above Estimate

    Investors Business Daily

  17. Amgen Q4 Sales, 2013 Guidance Modestly Beat Estimates

    Investors Business Daily

  18. The Dividend Kings List Keeps Expanding

    GuruFocus

  19. Johnson & Johnson Targeted By Short-Term Option Traders

    By SchaeffersResearch

  20. J&J EPS tops, recalls hit sales

    Investors Business Daily

  21. Should Johnson & Johnson Unload Troubled McNeil Consumer ...

    YCharts

  22. J&J Profit Tops, Tylenol Recall Hurts Sales

    Investors Business Daily

  23. Futures Restless And Mixed; Verizon, ARM Holdings Slip

    Investors Business Daily

  24. J&J's 4Q Beats, Outlook Disappoints

    FOXBusiness

  25. Futures Tread Water; Earnings in Focus

    FOXBusiness

  26. Stocks Tick Lower on Weak Housing Data

    FOXBusiness

  27. Benzinga Market Primer: Tuesday, January 22

    Benzinga

  28. US Stock Futures Flat Ahead Of Economic Data, Earnings

    Benzinga

  29. Earnings Scheduled For January 22, 2013

    Benzinga

  30. Stocks To Watch For January 22, 2013

    Benzinga

  31. Earnings Expectations for the Week of January 21

    Benzinga

  32. The Week Ahead: Tech Earnings in Focus

    Benzinga

  33. Week Ahead: Apple Earnings, Housing Data

    FOXBusiness

  34. S&P Highlights 1 ETF For Lengthy Streaks of Dividend Increases

    Benzinga

  35. Live Up To Principles To Gain Competitive Edge

    Investors Business Daily

  36. Live Up To Principles To Gain Competitive Edge

    Investors Business Daily

  37. BlackRock Fund Manager on How to Value Dividend Growth: 3 Stocks

    YCharts

  38. 9 High-Rated, Lower-Debt Dividend Stocks with a Reasonable Payout

    GuruFocus

  39. UPDATE: Jefferies & Company Reiterates Hold Rating, Raises PT on ...

    Benzinga

  40. Shiller PE Continues to Mislead Investors, the S&P 500 Is Fairly ...

    GuruFocus

  41. Stryker Corporation (SYK) Dividend Stock Analysis

    GuruFocus

  42. 4 Dividend Stocks to Avoid The Social Security Blues

    GuruFocus

  43. Celgene Stock Hits New High On Analyst Upgrades

    Investors Business Daily

  44. 4 Health Care ETFs Your Broker Forgot to Mention

    Benzinga

  45. Seven companies expected to grow dividends in 2013

    GuruFocus

  46. A Look Ahead: This Week's ETFs to Watch

    Benzinga

  47. UPDATE: Deutsche Bank Upgrades Johnson & Johnson to Buy on ...

    Benzinga

  48. A Peek Into The Market Before The Trading Starts

    Benzinga

  49. Benzinga's Top Upgrades

    Benzinga

  50. Meet Lou Simpson, Former Investment Star at Berkshire and New ...

    GuruFocus

  51. Pfizer's Anti-Rheumatoid Arthritis Pill, Potential Blockbuster, ...

    YCharts

  52. Good News For Pharma Stocks: FDA Drug Approval Speedier

    YCharts

  53. US Stock Futures Higher On Fiscal-Cliff Deal

    Benzinga

  54. Stocks To Watch For January 2, 2013

    Benzinga

  55. Bristol-Myers, Pfizer drug OK'd

    Investors Business Daily

  56. J&J's TB drug gets FDA nod

    Investors Business Daily

  57. Sectors to Monitor While the Nation Hangs from the Fiscal Cliff

    GuruFocus

  58. Stocks, Volume Surge On Reports Fiscal Deal Is Near

    Investors Business Daily

  59. Stocks Ramp Up As Deal Nears; Nasdaq Retakes Key Levels

    Investors Business Daily

  60. Stocks Burst Higher On Hopes Of Fiscal Cliff Deal

    Investors Business Daily

  61. J&J's Drug-Resistant Tuberculosis Treatment Approved

    Investors Business Daily

  62. Bristol-Myers, Pfizer Stocks Rise On Eliquis Approval

    Investors Business Daily

  63. Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

    Benzinga

  64. Abbott Laboratories (ABT) Dividend Stock Analysis

    GuruFocus

  65. 9 High-Yielding Mega-Cap Stocks

    GuruFocus

  66. The Best Dogs of the Dow Jones as of December 2012

    GuruFocus

  67. A Growth ETF for 2013

    Benzinga

  68. Ken Fisher's 3 Highest Yielding Dividend Stocks in Q3

    GuruFocus

  69. 3 of George Soros' Quantum Fund's Most Loved Stocks

    GuruFocus

  70. Abbott Laboratories: Quality Dividend Aristocrat for Long Term ...

    GuruFocus

  71. J&J to Host Analyst Meeting at 8:30AM EST on Jan. 22nd

    Benzinga

  72. Uh-Oh: Hedge Fund Managers Are Super-Bullish – Often a Bad Sign

    YCharts

  73. Prem Watsa's RFP Stake Gets Bigger

    GuruFocus

  74. The Fiscal Cliff...Opportunity Or Doomsday?

    GuruFocus

  75. S&P Sees Better 2013 For Health Insurance Providers

    Benzinga

  76. "$2-Billion Man" Prem Watsa Revisited, Plus His Profit-Generating ...

    GuruFocus

  77. Amgen To Pay $762M To Settle Drug Misbranding Case

    Investors Business Daily

  78. These 2 Dow Laggards Could Rebound in 2013

    Benzinga

  79. Barron's Recap (12/15/12): Outlook for 2013

    Benzinga

  80. Babbling Buyback Baffoons, Round 2

    GuruFocus

  81. Babbling Buyback Buffoons, Round 2

    GuruFocus

  82. AstraZeneca, Lilly Arthritis Drugs Flop In Trials

    Investors Business Daily

  83. A Unique Period of Time... Continued

    GuruFocus

  84. J&J's Janssen R&D Submits NDA for Canagliflozin/Metformin ...

    Benzinga

  85. J&J's Dividend, Yielding 3.5%: What You Need to Know About Cash ...

    YCharts

  86. A Look at Fortune's Health Care Picks for 2013 (ALGN, FMS, GILD)

    Benzinga

  87. J&J's EVARREST Fibrin Sealant Patch Approved by FDA

    Benzinga

  88. The Secret Ingredient of Dividend Growth Stocks

    GuruFocus

  89. J&J Says New Long-Term Study Suggests Lower Morality in ...

    Benzinga

  90. Stem Cell Research Gets Boost From New Cell Bank

    Investors Business Daily

  91. Warren Buffett's Best-Yielding Dividend Stocks

    GuruFocus

  92. The Other Healthcare Stocks of Warren Buffett

    GuruFocus

  93. Donald Yacktman Finds Two Undervalued Companies in His Most ...

    GuruFocus

  94. If You'd Bought Muni Bonds Shortly After Meredith Whitney's ...

    YCharts

  95. The Top Stocks Warren Buffett and Donald Yacktman Agree On

    GuruFocus

  96. Merck races to beat Lilly debut

    Investors Business Daily

  97. Alzheimer Failures Elsewhere Don't Deter Merck: Phase II/III Study ...

    YCharts

  98. Merck Alzheimer's Drug Trial Challenges Lilly's Lead

    Investors Business Daily

  99. Hedge Fund Profile: Tiger Global Management

    Benzinga

  100. BioMarin, Prestige Brands and Other Top Performing Health Care ...

    Benzinga
People viewing JNJ also viewed: , , , , , ,
Marketplace
Trading Center